Chemotherapy, FDA and Vaccines - Pharmacy Technician Pulse

What side effects to expect from the shingles vaccine

The Checkup by Singlecare

SEPTEMBER 12, 2023

Luckily, there’s a shot to help prevent it: Shingrix, the shingles vaccine. The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California.

Vaccines

Vaccines Immunization Pharmacy Program Director Chemotherapy

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy

Chemotherapy Immunization Compounding Pharmacies Hospitals

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Compounding

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 23, 2025

The FDA's decision represents progress in treating EGFR-mutated NSCLC beyond initial therapy lines. SHOW MORE Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.

FDA

FDA Compounding Pharmacies Chemotherapy Immunization

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

JUNE 11, 2025

The FDA approved taletrectinib (Ibtrozi; Nuavtion Bio Inc) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). It demonstrated high response rates with durable benefit and intracranial activity and was well-tolerated among patients, according to the FDA.

FDA

FDA Compounding Pharmacies Immunization Hospitals

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. N Engl J Med. 2019;380:2020-2030. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA

FDA Compounding Pharmacies Dosage Hospitals

FDA pulls AZ’s Evusheld for COVID, citing lack of efficacy

pharmaphorum

JANUARY 27, 2023

AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US. and other XBB subvariants, said the FDA in an update. Evusheld is also ineffective against the BQ.1,

FDA

FDA Chemotherapy Immunization Vaccines

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

pharmaphorum

SEPTEMBER 16, 2021

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exkivity. The post Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval appeared first on.

FDA

FDA Chemotherapy Vaccines

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

JUNE 11, 2025

Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. In October 2024, CAR T therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) received FDA regenerative medicine advanced therapy designation as a first-line treatment for high-risk large B-cell lymphoma.

Compounding

Compounding Compounding Pharmacies FDA Immunization

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Dalton shared her surprise about how variability in manufacturing affects the patient experience, given that some products created using the patient’s cells may not always be usable or up to FDA standards. 2 For Dyke’s team, balancing research and commercial pathways have created gray areas.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

JUNE 18, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Immunization

Immunization Compounding Pharmacies Hospitals Chemotherapy

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage

Dosage Compounding Pharmacies Immunization Chemotherapy

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The FDA has gone on to grant a fast review of the results ahead of a regulatory decision on the new lung cancer indication next year. months, compared with 6.7

FDA

FDA Chemotherapy Compounding Vaccines

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

JUNE 12, 2025

Darkow noted that, unlike a “typical” medication, biologics are larger, and for these reasons, products can encompass a wide range of types of forms, such as certain vaccines, blood products, monoclonal antibodies, cellular therapies, and insulin. The FDA approval process for biologics is lengthier compared with biosimilars.

Immunization

Immunization Compounding Pharmacies FDA Hospitals

Microbiome therapies: a maturing movement

European Pharmaceutical Review

JUNE 27, 2023

Of note, the US Food and Drug Administration (FDA) and ANSM (French regulatory authorities) have established themselves as early leaders to develop guidelines. Since these fresh FDA approvals for microbiome-based therapies, regulatory pathways are becoming clearer and opening new perspectives for companies.

Chemotherapy

Chemotherapy Immunization FDA Vaccines

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

Pharmacy Times

JUNE 17, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now! Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. I know the FDA is very interested in using real-world data to help inform and confirm some of the benefits that we are seeing in trials. We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies

Compounding Pharmacies Immunization Hospitals Compounding

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Pharmacy Times

JUNE 6, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Compounding

FDA gives Ferring go-ahead for Adstiladrin gene therapy manufacturing

Pharmaceutical Technology

JUNE 13, 2023

The US Food and Drug Administration (FDA) approved Ferring Pharmaceuticals’ Prior-Approval Supplement (PAS) to the Biologics License Application (BLA) for the bladder cancer gene-therapy Adstiladrin (nadofaragene firadenovec). Non-muscle invasive bladder cancer is characterised by cancer cells that remain only in the lining of the bladder.

FDA

FDA Vaccines Chemotherapy Communication

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Compounding

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

SEPTEMBER 8, 2020

In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. Unpleasant truth: let’s embrace it and take action.

Chemotherapy

Chemotherapy Patient Care Vaccines FDA

Pembrolizumab by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Pharmaceutical Technology

MARCH 2, 2023

Keytruda is indicated in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. It is also indicated for the treatment of metastatic transitional (urothelial) tract cancer and gastric cancer.

Chemotherapy

Chemotherapy FDA Vaccines Immunization

Decline of novel drug approvals means less business for cutting-edge CMOs

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. Increased reluctance to authorise innovative and unproven drugs for use, stemming from the FDA’s experience with Aduhelm, reduced the overall novel approvals in 2022. months longer on the treatment.

FDA

FDA Chemotherapy Vaccines

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Pharmacy Times

JUNE 9, 2025

The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment. A 5-year follow-up confirmed sustained overall survival benefits, with a notable reduction in mortality risk for patients achieving pathological complete response.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Compounding

Enbrel vs. Cosentyx: Differences, similarities & side effects

The Checkup by Singlecare

SEPTEMBER 12, 2024

Both are brand-name drugs approved by the Food and Drug Administration (FDA) and are given as subcutaneous injections. They also have different FDA approvals for some conditions. Enbrel is FDA approved for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Insurance

Insurance Dosage Labelling Vaccines

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

SHOW MORE The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma. The phase 3 ECHO trial showed significant progression-free survival improvement with acalabrutinib, supporting its approval as a new standard of care for untreated MCL.

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Complex Medicines: A multi-billion-pound addition to the UK life sciences industry

pharmaphorum

JULY 19, 2021

Recent successes in FDA approvals of antibody–drug conjugates (ADCs), RNA therapeutics and the UK’s regulatory leadership in coronavirus vaccines show that complex medicines are having a global impact. But the benefits of complex medicines go far beyond those we have seen with these vaccines.

Vaccines

Vaccines Chemotherapy FDA

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Compounding

ASCO 2025: Evaluating Nivolumab Plus Relatlimab in Resected Stage 3 or 4 Melanoma

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Compounding

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Pharmacy Times

JUNE 25, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Compounding

FDA fast-tracks Leap’s gastric cancer immunotherapy

pharmaphorum

SEPTEMBER 25, 2020

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regulator. The post FDA fast-tracks Leap’s gastric cancer immunotherapy appeared first on.

FDA

FDA Immunization Chemotherapy Hospitals

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

The potential of bispecific antibodies in blood cancer care and beyond

Hospital Pharmacy Europe

FEBRUARY 15, 2024

They are] administered by the same nurses who would normally give chemotherapy’, Dr Tucker says. However, she adds that ‘approaches using, for example, T-cell stimulating vaccines are currently being explored’. Undoubtedly, much more research, development and clinical applications of bispecific antibodies can be expected.

Chemotherapy

Chemotherapy Hospitals Immunization Vaccines

GSK hits another oncology hurdle as Zejula use is limited again

pharmaphorum

NOVEMBER 14, 2022

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with a specific mutation. That was due last Friday, but cancelled when GSK opted to withdraw the approval.

Labelling

Labelling Chemotherapy FDA Vaccines

What side effects to expect from the shingles vaccine

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

Trending Sources

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

FDA pulls AZ’s Evusheld for COVID, citing lack of efficacy

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacies Need Strategies to Improve Health Care Access

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

2020 review – Pharma’s progress outside of COVID-19

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Microbiome therapies: a maturing movement

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

FDA gives Ferring go-ahead for Adstiladrin gene therapy manufacturing

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

Pembrolizumab by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Decline of novel drug approvals means less business for cutting-edge CMOs

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Enbrel vs. Cosentyx: Differences, similarities & side effects

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Complex Medicines: A multi-billion-pound addition to the UK life sciences industry

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

ASCO 2025: Evaluating Nivolumab Plus Relatlimab in Resected Stage 3 or 4 Melanoma

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

FDA fast-tracks Leap’s gastric cancer immunotherapy

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

The potential of bispecific antibodies in blood cancer care and beyond

GSK hits another oncology hurdle as Zejula use is limited again

Stay Connected